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Abstract: SPG23 is an autosomal recessive neurodegenerative subtype of lower limb spastic
paraparesis with additional diffuse skin and hair dyspigmentation at birth followed by
further patchy pigment loss during childhood. Previously, genomewide linkage in an
Arab-Israeli pedigree mapped the gene to an approximately 25-cM locus on
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chromosome 1q24-q32. Using whole-exome sequencing in a further Palestinian-
Jordanian SPG23 pedigree we identified a complex homozygous 4-kb deletion/20-bp
insertion in DSTYK (dual serine-threonine and tyrosine protein kinase) in all four
affected family members. DSTYK is located within the established linkage region and
we also found the same mutation in the previously reported pedigree and another
Israeli pedigree (total of 10 affected individuals from three different families). The
mutation removes the last two exons and part of the 3'UTR of DSTYK. Skin biopsies
revealed reduced DSTYK protein levels along with focal loss of melanocytes.
Ultrastructurally, swollen mitochondria and cytoplasmic vacuoles were also noted in
remaining melanocytes, and some keratinocytes and fibroblasts. Cultured
keratinocytes and fibroblasts from an affected individual, as well as knockdown of
Dstyk in mouse melanocytes, keratinocytes and fibroblasts, were associated with
increased cell death following ultraviolet irradiation. Keratinocytes from an affected
individual showed loss of kinase activity upon stimulation with fibroblast growth factor.
Previously, dominant mutations in DSTYK were implicated in congenital urological
developmental disorders, but our study identifies different phenotypic consequences
for a recurrent autosomal recessive deletion mutation in revealing the genetic basis of
SPG23.
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Abstract 
SPG23 is an autosomal recessive neurodegenerative subtype of lower limb spastic paraparesis with 
additional diffuse skin and hair dyspigmentation at birth followed by further patchy pigment loss 
during childhood. Previously, genomewide linkage in an Arab-Israeli pedigree mapped the gene to 
an approximately 25-cM locus on chromosome 1q24-q32. Using whole-exome sequencing in a 
further Palestinian-Jordanian SPG23 pedigree we identified a complex homozygous 4-kb 
deletion/20-bp insertion in DSTYK (dual serine-threonine and tyrosine protein kinase) in all four 
affected family members. DSTYK is located within the established linkage region and we also found 
the same mutation in the previously reported pedigree and another Israeli pedigree (total of 10 
affected individuals from three different families). The mutation removes the last two exons and 
part of the 3’UTR of DSTYK. Skin biopsies revealed reduced DSTYK protein levels along with focal loss 
of melanocytes. Ultrastructurally, swollen mitochondria and cytoplasmic vacuoles were also noted in 
remaining melanocytes, and some keratinocytes and fibroblasts. Cultured keratinocytes and 
fibroblasts from an affected individual, as well as knockdown of Dstyk in mouse melanocytes, 
keratinocytes and fibroblasts, were associated with increased cell death following ultraviolet 
irradiation. Keratinocytes from an affected individual showed loss of kinase activity upon stimulation 
with fibroblast growth factor. Previously, dominant mutations in DSTYK were implicated in 
congenital urological developmental disorders, but our study identifies different phenotypic 
consequences for a recurrent autosomal recessive deletion mutation in revealing the genetic basis of 
SPG23. 
Main text 
The hereditary spastic paraplegias (HSPs) are a group of inherited disorders characterized by 
spastic paralysis of the lower limbs. The genetic basis of HSPs is complex, with more than 70 
subtypes.1 Among these, spastic paraplegia type 23 (SPG23; MIM 270750) is a rare subtype 
presenting in childhood with progressive spastic paraplegia associated with peripheral neuropathy, 
4 
 
skin pigment abnormalities (i.e. vitiligo, hyperpigmentation, diffuse lentigines) and premature 
graying of hair. To date, only five reports have been documented (Table S1).2-6 The affected 
individuals in three of these reports were from the Middle East (two Arab-Israeli and one 
Jordanian),2-4 another individual was of North European descent,5 and the most recent case was 
from India.6 In the Arab-Israeli family originally reported in 1985,4 linkage analysis mapped the 
causative gene to a 25-cM region on chromosome 1q24-q32 (maximum LOD score of 3.05).7 This 
interval contained approximately 276 genes but no candidate gene and pathogenic mutations were 
identified. 
To identify mutations that cause SPG23, we investigated an additional, previously 
unreported, Kuwaiti-Jordanian family (Family 1) containing four affected individuals with evidence of 
autosomal recessive inheritance (Figure 1A). The proband, a 22-year-old male Palestinian (individual 
IV-5), presented with life-long silvery-gray hair on the scalp, eyebrows (Figure 1B) and eyelashes; his 
beard area (Figure 1C) and secondary sexual hair were also affected by focal pigment loss after 
puberty. In addition, during childhood he had patchy pigmentary changes on his skin with later onset 
(early 20s) of more depigmented, vitiligo-like lesions on the lips, hands and forearms (Figure 1D and 
1E). He developed a waddling gait from the age of 2-3 years with subsequent emergence of spastic 
paraplegia requiring wheelchair use from the age of 9 years. He is of normal intelligence, and there is 
no history of epilepsy, sensorineural deafness, or other motor or sensory neurologic manifestations. 
He is the 3rd of 6 living siblings from a parent-related (1st cousin) family, and his younger brother (IV-
8) and two female cousins (VI-1 and VI-2) have similar phenotypes. His bladder function is normal 
but he and his younger brother both experience bowel urgency and incontinence. The younger 
brother also experienced convulsions at the age of 6 years following a high-grade fever. In the 
proband (IV-5), laboratory tests (full blood count and serum biochemistry) were all unremarkable. 
Brain magnetic resonance imaging showed no gross abnormalities. An X-ray of his hips showed 
bilateral dislocation. Ultrasound of his abdomen and pelvis revealed a horseshoe kidney 
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malformation, although no urogenital anomalies were detected in his affected brother (IV-8); 
screening has not yet been undertaken in either of the 2 other affected family members.  
To identify the underlying molecular genetic defect in these individuals, we obtained blood 
for genetic testing and skin samples (ellipse of skin taken under local anesthesia by 1% lignocaine) 
from members of this family in adherence to the Declaration of Helsinki. Whole-exome sequencing 
was performed using genomic DNA extracted from peripheral blood from all affected individuals and 
their respective parents. Whole-exome capture was performed on these eight samples using in-
solution hybridization (Agilent All Exon V4) and sequence data was generated on the Illumina HiSeq 
2000 (San Diego, CA, USA). The reads produced were aligned to the reference human genome using 
the NovoAlign software package (Novocraft Technologies Sdn Bhd). Duplicate reads, arising from 
PCR clonality or optical duplicates, and reads mapping to multiple regions were removed from 
downstream analysis. A summary of exome coverage data is presented in Table S2. 
Whole-exome sequencing failed to reveal any rare, pathogenic homozygous single 
nucleotide variants or indels, which were present in all four affected individuals. However, we 
observed two blocks of homozygosity which were shared among all four affected individuals, namely 
a 9.9 Mb block at chromosome 1q32 and a 4.4 Mb block at chromosome 9p13. Because the SPG23 
locus had previously been mapped to chromosome 1q24-q32,7 we analyzed copy number variation 
(CNV) data using the ExomeDepth software package8 and identified a putative homozygous 
intragenic deletion in DSTYK in each of the affected individuals, which completely removed the last 
two exons (12 and 13) along with part of the 3’UTR (Figure 1F). Using a ‘primer walk’ approach, the 
precise breakpoints of the deletion in intron 11 and the 3’UTR were identified (Figure 1G), with 
coordinates from chromosome 1:205,145,663-205,149,750 (GRCh38/hg38 assembly). This mutation 
was absent from an in-house exome bank and public databases, including DECIPHER,9 Database of 
Genomic Variants10 and Copy Number Variation in Disease.11 Intriguingly, this 4-kb deletion was 
accompanied by the insertion of an intervening 20-bp sequence. Using the Basic Local Alignment 
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Search Tool (BLAST), this sequence was shown to originate from 5,765-bp downstream of the 
original stop codon (chr1:205,141,774-205,141,793) and inverted prior to re-insertion. Additionally, 
all affected individuals carried the common SNP rs3902193. Complex CNVs similar to the mutation 
identified here have previously been reported to be associated with human genetic disease.12,13 We 
then assessed correlation of the mutation with disease status in the rest of the family by designing 
two further pairs of allele specific primers to selectively amplify the wild-type and mutant alleles 
(Table S3) and confirmed that this deletion in DSTYK fully segregates with phenotype (Figure S1).  
Next, we investigated whether the previously reported Arab-Israeli pedigree (Family 2) 
linked to 1q24-q327 and another unreported Israeli family (Family 3) with an SPG23 phenotype also 
carried a recessive mutation in DSTYK. We found that the affected individuals in these two families 
also carried the same intragenic deletion, and this mutation also segregated with phenotype in the 
rest of the family (Figure S2 and S3). Because all three pedigrees originated from the Middle East, we 
explored the possibility that the deletion in DSTYK may represent a founder mutation and that these 
families may be distantly related. Using a number of microsatellite markers around the DSTYK locus 
(Figure S4), we found that the three families had a shared haplotype around the mutation, but with 
a refined area of linkage of approximately 9.6-cM between D1S413 and D1S2692. DSTYK is included 
within the new interval (along with 202 other genes).   
DSTYK, also known as Dusty protein kinase, receptor interacting protein 5 (RIP5) or RIP 
kinase 5 (RIPK5), encodes dual serine-threonine and tyrosine protein kinase, an enzyme implicated 
as a regulator of cell death.14 DSTYK was found to induce both caspase-dependent and caspase-
independent cell death in a dose-dependent manner,14 although subsequent studies have 
challenged the notion that DSTYK is a RIP5 family member.15,16 DSTYK mRNA is expressed in multiple 
tissues, although normalized expression distribution is highest in the spinal cord, pineal gland and 
skin according to the SOURCE database.17 With regard to human disease, heterozygous mutations in 
DSTYK were identified as a frequent cause of autosomal dominant congenital anomalies of the 
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kidney and urinary tract-1 (CAKUT1; MIM 610805).18 Notably, DSTYK mutations were found in 2.3% 
of CAKUT1 cases, suggesting that DSTYK is a major determinant of human urinary tract 
development.18 Interestingly, amongst individuals with these autosomal dominant DSTYK mutations, 
three family members with a splice site mutation had epilepsy and an unrelated individual with a 
nonsense mutation experienced early-onset ataxia. Nevertheless, no skin or pigmentary changes 
were associated with these heterozygous mutations.18 
Next, we assessed DSTYK pathology in skin, following written and informed consent 
according to a protocol approved by the St Thomas’ Hospital Ethics Committee (Molecular basis of 
inherited skin disease: 07/H0802/104). Peri-lesional skin biopsies were obtained from the leg of 
affected individual IV-5 of Family 1, and assessed using immunofluorescence and transmission 
electron microscopy (see Table S5 for antibody details). Immunofluorescence microscopy of DSTYK 
using both N-terminal and C-terminal antibodies showed markedly reduced labeling (Figure 2A and 
2B) in the IV-5 skin compared to controls. Transmission electron microscopy revealed focal loss of 
melanocytes with some of the remaining melanocytes showing ultrastructural features of swollen 
mitochondria and cytoplasmic vacuoles (Figure 2C), but these abnormalities were not present in 
apparently unaffected melanocytes in the same affected individual (Figure S8). These enlarged 
mitochondria with abnormal cristae were also observed in other cell types such as fibroblasts and 
keratinocytes (Figure 2D). These pathological findings indicate an increased susceptibility of mutant 
cells to stress and cell death. 
To further explore the potential role for DSTYK in regulating cell death, primary fibroblasts 
and keratinocytes from this affected individual were isolated for further analysis, with the 
keratinocytes immortalized at passage 1. We also generated Dstyk siRNA knockdown mouse 
fibroblasts, keratinocytes and melanocytes to determine whether siRNA depleted cells and cells 
from affected individuals exhibited similar phenotypes. We first assessed whether loss of DSTYK 
resulted in increased cell death. Cells were exposed to a UV illuminator for 2 minutes, fixed after 9 
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hours and apoptosis levels determined by analysis of total cell number as a readout for cell death. 
For all cell types, both Dstyk knockdown and mutant cells exhibited increased cell death 9 hours 
after exposure to UV as shown by loss of cell attachment (Figure 3A-E). There were no differences in 
cell death between Dstyk depleted and control cells under basal conditions (data not shown). As 
alternative readouts for UV-induced apoptosis, cleaved caspase-3 staining was also assessed and 
apoptotic markers were analyzed by FACS analysis following UV treatment. A significant increase in 
cells positive for cleaved caspase-3 staining was observed in DSTYK-depleted keratinocytes and 
melanocytes following 9 hours of UV exposure (Figure S5A-C); FACS analysis also revealed an 
increase in Annexin V and 7-AAD labeling in mutant fibroblasts compared to controls, reflecting an 
increase in both early and late apoptotic markers (Figure S5D), which confirmed the increased 
susceptibility to apoptotic signaling due to the loss of DSTYK protein. To assess whether loss of 
DSTYK altered mitochondrial architecture, we stained live knockdown and mutant cells with 
MitoTracker Red followed by fixation and analysis by confocal microscopy. All cell types showed 
dispersed and enlarged mitochondrial organization in response to UV, however no marked changes 
in this response were observed in Dstyk knockdown or mutant cells compared to control cells (Figure 
S6A-C and data not shown). DSTYK has previously been shown to be a positive regulator of 
extracellular signal-regulated kinase (ERK) phosphorylation downstream of FGF stimulation in 
HEK293T cells.18 We therefore determined whether cells from affected individuals showed loss of 
pERK activity upon FGF stimulation. Biochemical analysis demonstrated that primary mutant 
keratinocytes showed significantly reduced pERK activation in response to FGF stimulation 
compared to control cells (Figure S7A and S7B) confirming previous observations on the role of 
DSTYK in regulating FGF signaling.  
Our study indicates that the molecular basis of SPG23, at least in three pedigrees, involves a 
large 3’ deletion in DSTYK, and thus two specific disease entities, SPG23 and CAKUT1, harbor 
mutations in the same gene. Aside from the different mode of inheritance, the heterozygous 
mutations in CAKUT1 have been mostly upstream of the kinase domain, with the exception of one 
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missense mutation in exon 12.18 In contrast, the intragenic deletion we identified occurs near the C-
terminus and appears to lead to reduction of protein levels. Nevertheless, a minor overlap in 
phenotype occurs – with the SPG23 proband in our study also having a structural renal anomaly, and 
some neurologic features being described in CAKUT1. Overall, the lack of urinary tract abnormalities 
in heterozygotes and some homozygotes in the three SPG23 pedigrees presented in our study 
indicates that this novel deletion has a distinct functional impact. Morpholino knockdown of dstyk in 
zebrafish was shown to result in a wide spectrum of defects including growth retardation, abnormal 
tail morphogenesis, loss of heartbeat, cloacal malformations and abnormalities in jaw 
development.18 Dstyk kinase domain-knockout mice showed impaired learning and memory 
capabilities but had no significant morphological defects.19 The apparent discrepancy between the 
features seen in mutant mice with CAKUT1 and SPG23 cases may be due to the fact that full-length 
DSTYK was not ablated in these mice and a truncated protein may still have been present.19 
Moreover, our data suggest that DSTYK acts to suppress apoptosis in response to UV-induced stress, 
the response to which remains unknown in animal models of DSTYK dysfunction.   
Our data suggest that loss of DSTYK in fibroblasts, keratinocytes and melanocytes leads to 
increased susceptibility to apoptosis (quantified by cell number, cleaved caspase-3 staining and FACS 
analysis). Various modalities of cell death can occur, including necrosis, necroptosis and pyroptosis,20 
and mitochondrial swelling has also been associated with non-apoptotic forms of programmed cell 
death.21 DSTYK has previously been proposed to be a positive regulator of both caspase-dependent 
and independent cell death pathways.14 However, this was shown to occur only following 
overexpression of DSTYK in HEK293 cells and in the absence of external stress stimuli. Our data 
shows that in the context of skin, DSTYK plays a predominant role in suppressing caspase-dependent 
apoptosis in response to UV stress in a range of dermal cell types. Future studies will focus on 
understanding the mechanisms by which DSTYK contributes to apoptosis protection. 
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One pertinent clinical feature in the skin in individuals with SPG23 is loss of skin pigment: 
some of this pathology may reflect post-inflammatory hypopigmentation but certain lesions show 
complete depigmentation in keeping with vitiligo, a common complex disorder associated with 
autoimmune destruction of melanocytes in skin and hair. Other cases of vitiligo may show familial 
clustering although inheritance is non-Mendelian and multi-factorial.22 To date, approximately 40 
loci with convincing or strongly suggestive evidence for a role in vitiligo susceptibility have been 
identified,23 although there has been no association with DSTYK or its locus on 1q32.1, indicating 
that DSTYK may not be involved in common complex versions of this condition. The vitiligo in our 
cases likely reflects localized cell killing of melanocytes, although how the deletion in DSTYK 
preferentially leads to melanocyte loss is uncertain, particularly given the presence of abnormal 
vacuoles and swollen mitochondria in several skin cell types, including melanocytes, keratinocytes 
and fibroblasts. Both melanocytes and Schwann cells are derived from the neural crest, and these 
two distinct cell types have been proposed to originate from a common post-neural crest progenitor, 
namely the Schwann cell precursor.24 The motor and pigmentary symptoms in individuals with 
SPG23 may be a manifestation of increased vulnerability of Schwann cell precursors to cell death, 
but further studies in appropriate model systems are needed to dissect the underlying 
pathomechanisms of this unique disorder. 
 In summary, we have identified a large intragenic deletion in DSTYK as the molecular basis 
for three families with SPG23, an autosomal recessive disorder characterized by spastic paraparesis 
and dyspigmentation. Our data in skin tissue also indicate the clinical consequences of abnormal cell 
death, highlighting findings of potential relevance to other more common disease processes in the 
skin, such as vitiligo and other dyspigmentary dermatoses. 
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Figure legends 
Figure 1. Pedigree and Molecular Pathology of SPG23  
(A) The family pedigree of Family 1. Squares denote male family members, and circles female family 
members; filled-in symbols indicate clinically affected individuals. The triangle (IV-2) refers to a 
spontaneous abortion. 
(B) Affected individual IV-5 with gray/white hair in the scalp and eyebrows and dyspigmentation on 
the forehead.  
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(C) Similar changes affecting hair follicle pigmentation are present in the beard area (individual IV-5).  
(D) Blotchy dyspigmentation, hypopigmentation and depigmentation on the dorsum of the hands 
with marked pigment loss and some erythema around the finger nails.  
(E) Loss of skin pigment (vitiligo-like lesions) on the flexural aspects of the wrists and forearms 
(individual IV-5).  
(F) Integrative Genomics Viewer analysis reveals homozygous loss of exons 12 and 13 and part of the 
3’ UTR of DSTYK in affected individuals IV-5, IV-8, VI-1 and VI-2. Heterozygous changes are implicated 
in the parental samples (III-3, III-4, V-1 and V-2).  
(G) Schematic of DSTYK to show the homozygous mutation and Sanger sequencing confirmation of 
the 4-kb deletion/20-bp insertion in genomic DNA (affected individual IV-5). The schematic also 
illustrates the previous mutations in DSTYK identified in a different disorder, autosomal dominant 
congenital anomalies of the kidney and urinary tract-1 (CAKUT1).  
 
Figure 2.  Skin Pathology in SPG23  
(A) Immunofluorescence microscopy using a DSTYK N-terminal antibody (NBP1-92336, 1:500, Novus 
Biologicals) in normal skin (top) reveals bright pan-epidermal cytoplasmic staining with focal 
accentuation in basal epidermal melanocytes and dermal fibroblasts. In affected individual (IV-5) 
skin (middle panel) there is markedly reduced labeling, with an absence of staining in the negative 
control (scale bar represents 100 μm).  
(B) Immunofluorescence microscopy using a DSTYK C-terminal antibody (sc-374487, 1:500, Santa 
Cruz Biotechnology) in normal skin (top) reveals bright pan-epidermal cytoplasmic staining with focal 
accentuation in basal epidermal melanocytes and dermal fibroblasts. In affected individual (IV-5) 
skin (middle panel) there is markedly reduced labeling, with an absence of staining in the negative 
control (scale bar represents 100 μm).  
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(C) Transmission electron micrograph of a melanocyte (affected individual IV-5) shows prominent 
mitochondria and abnormal cytoplasmic vacuoles (asterisk) (scale bar represents 2 μm).  
(D) Transmission electron micrograph of a keratinocyte (affected individual IV-5) shows prominent 
swollen mitochondria with abnormal cristae (asterisks) (scale bar represents 2 μm).  
 
Figure 3. Increased sensitivity to apoptosis in DSTYK null cells 
(A) Western blots of DSTYK protein levels in mouse NIH-3T3 fibroblasts transfected with non-
targeting siRNA (Control) or siRNA pool specifically targeted to Dstyk (Dstyksi). Graph shows 
percentage of total starting cells attached 9 hours after UV illumination. Values are means +/- 
standard error of the mean (SEM). Representative of 3 independent experiments. * denotes p<0.05. 
(B) Western blots of DSTYK protein levels in human fibroblasts isolated from healthy donors 
(Control) or affected individual (IV-5). Graph shows percentage of total starting cells attached 9 
hours after UV illumination. Values are means +/- SEM. Representative of 3 independent 
experiments. * denotes p<0.05. 
(C) Western blots of DSTYK protein levels in mouse keratinocytes transfected with non-targeting 
siRNA (Control) or siRNA pool specifically targeted to Dstyk (Dstyksi). Graph shows percentage of 
total starting cells attached 9 hours after UV illumination. Values are means +/- SEM. Representative 
of 3 independent experiments. * denotes p<0.05. 
(D) Western blots of DSTYK protein levels in human keratinocytes isolated from healthy donors 
(Control) or affected individual (IV-5). Graph shows percentage of total starting cells attached 9 
hours after UV illumination. Values are means +/- SEM. Representative of 3 independent 
experiments. * denotes p<0.05. 
(E) Western blots of DSTYK protein levels in mouse melanocytes transfected with non-targeting 
siRNA (Control) or siRNA pool specifically targeted to Dstyk (Dstyksi). Graph shows percentage of 
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total starting cells attached 9 hours after UV illumination. Values are means +/- SEM. Representative 
of 3 independent experiments. * denotes p<0.05. 
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